Residual Cancer clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    open to eligible people ages 18 years and up

    The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: - Sacituzumab govitecan - Atezolizumab

    at UCSF

Our lead scientists for Residual Cancer research studies include .

Last updated: